Finally, MBP determined significantly higher AL and OM risks (Fig. 3), confirming the available evidence from randomized trials [1–4] and the findings of a recent propensity score-matched comparison of NBP vs. MBP alone performed on a more limited number of cases derived by the iCral database [5]. The gene discussed is MBP; the disease is ocular melanoma.